Novo, Bristol Myers-Squibb and Merck Group scored exits as the fibrosis and cancer drug developer priced its shares in the middle of the IPO's range.

Spun out of University of Louisville, Koligo Therapeutics has already launched its first cell therapy product and aims to commercialise a treatment for covid-19.

Novartis has bought Vedere Bio, a retinal disease therapy spinout of UC Berkeley also exploiting UPenn research, to expand its gene medicine capabilities.

Blue Venture Fund will exit the cancer diagnostics technology startup in a purchase by another of its investors, Exact Sciences, that could reach $2.15bn.

Banco Sabadell looks likely to have exited the digital signature software provider after Providence Equity Partners bought a majority stake.

The handcrafted product marketplace is set to list on TSE’s Mothers Market in a late November offering that will enable Globis, Japan Post, KDDI, Mitsui Fudosan, Mixi, SMBC and SBI to exit.

Exact Sciences has shelled out $410m to buy University of Oxford early cancer test company Base Genomics, incorporated in July 2019.

Exact Sciences is set to acquire Johns Hopkins spinout Thrive Earlier Detection for up to $2.15bn in cash and stock, including $1.7bn upfront.

Cybersecurity consulting services provider SEC Consult has agreed to be purchased in a deal that will allow Swisscom Ventures to exit.

University of Toronto's FPGA programming platform developer LegUp Computing has been acquired in a deal that allowed Intel Capital to exit.